Disclosed herein is a method of preparing a subject's cells for topical treatment of a subject in need. Also provided is a topical formulation and methods of treating a subject suffering a skin disorder and pain using the topical formulation. Also disclosed herein are devices and systems for micronizing an aspirate in preparation of such a topical formulation.

A method for capturing dislodged vegetative growth during a surgical procedure is provided. The method includes maneuvering, into a circulatory system, a first cannula having a distal end and an opposing proximal end, such that the first cannula is positioned to capture the vegetative growth en bloc. A second cannula is positioned in fluid communication with the first cannula, such that a distal end of the second cannula is situated in spaced relation to the distal end of the first cannula. A suction force is provided through the distal end of the first cannula so as to capture the vegetative growth. Fluid removed by the suction force is reinfused through the distal end of the second cannula. Subsequent to becoming dislodged, the vegetative growth is captured by the first cannula. A method for capturing a vegetative growth during removal of a pacemaker lead is also provided.

Implantable devices comprising a scaffold, cells, and/or therapeutic molecules are provided. Uses include inhibition of pathological immunity, elaboration of therapeutic growth factors, and immune augmentation. The implantable device may contain a porous substrate structure to which therapeutic cells are adherent, which can be implanted and explanted from a patient. In another embodiment, a medical device includes a porous substrate seeded with therapeutic cells, said device comprising of an additional layer allowing free exchange of molecules without cell escape. Said medical device is seeded with thymic medullary epithelial cells or progenitors of said thymic medullary epithelial cells. In conditions where tolerance to alloreactive donor cells is desired, the thymic medullary epithelial cells or progenitors thereof are derived from recipient cells. In conditions where tolerance to alloreactive recipient cells is desired, the thymic medullary epithelial cells or progenitors thereof are derived from donor cells.

Disclosed herein are implantable 3-dimensional large capacity device assemblies, specifically, large capacity device assemblies for encapsulating pancreatic progenitor cells for treatment of diabetes.

A conductive porous fabric can be formed, such as by using a template material. The porous fabric can be conductive, such as thick enough to be self-supporting, or supported such as by another structure. The porous fabric can be used in implantable or percutaneous applications, such as to provide an immunoisolation barrier. In another example, the fabric can be coupled to an electric potential, such as to facilitate gas evolution when the porous fabric is located in an aqueous medium. Such gas evolution can be used for various purposes, such as to maintain living cell viability by providing oxygen, or for self-cleaning. Illustrative examples of porous fabric materials include gold, platinum, palladium, iridium, niobium, or a form of carbon such as graphene.

Described herein are injection devices capable of automatically injecting substances into the soft tissue of a patient. The devices can inject low to high viscosity materials at predetermined, user selected injection rates, allowing the operator more control than a traditional syringe. The devices can allow mixing of more than one substance and/or reconstitution of a solid substance for injection. The injection devices described herein can allow the operator to easily inject one or more low to high viscosity liquid or gel soft-tissue augmentation fillers, one or more drugs, one or more other biocompatible materials, or combinations thereof.

A method of delivering cells to a target tissue is provided comprising depositing a hydrogel pre-gel comprising magnetic particle-loaded cells to the target tissue and, prior to or during gelation of the hydrogel, drawing the magnetic particle-loaded cells to the tissue with a magnetic field, followed by gelation of the hydrogel to lock the cells in place on the tissue. The cells may be mesenchymal stem cells, such as adipose-derived mesenchymal stem cells, and the target tissue may be adventitial tissue of an aneurysm in a blood vessel. Also provided are devices useful in the method.

A method for capturing dislodged vegetative growth during a surgical procedure is provided. The method includes maneuvering, into a circulatory system, a first cannula having a distal end and an opposing proximal end, such that the first cannula is positioned to capture the vegetative growth en bloc. A second cannula is positioned in fluid communication with the first cannula, such that a distal end of the second cannula is situated in spaced relation to the distal end of the first cannula. A suction force is provided through the distal end of the first cannula so as to capture the vegetative growth. Fluid removed by the suction force is reinfused through the distal end of the second cannula. Subsequent to becoming dislodged, the vegetative growth is captured by the first cannula. A method for capturing a vegetative growth during removal of a pacemaker lead is also provided.

A device for processing a biological material is disclosed. The device includes a syringe barrel comprising beads, a filter positioned at a close end of the barrel, a plunger insertable into the barrel through an open end, and a needle. The plunger includes a paddle assembly that is configured to mix a biological material with the beads after the biological material has been harvested from a patient.

An injection catheter system is disclosed. The system includes a catheter defining a first pressure transfer lumen adapted to retain a pressure transfer material, an actuator at a proximal end of the catheter adapted to deliver a pressure from a proximal end to a distal end of the first pressure transfer lumen via the pressure transfer material, a distal section defining at least a first internal chamber adapted to retain a therapeutic gel component, at least a first plunger retained in the first internal chamber, and an injection port for delivering a therapeutic gel component into a treatment location from the first internal chamber when the actuator is used to deliver a pressure via the pressure transfer material to move the first plunger to deliver a therapeutic gel component through the injection port.